T. Scott Reid

T. Scott Reid has extensive experience in the healthcare industry, particularly in the field of diagnostics and business development. T. Scott currently serves as the VP and Global Head of Diagnostics at SOPHiA GENETICS, where they lead efforts to commercialize the company's technology solutions and works with BioPharma clients to develop companion diagnostics and clinical trial assays. Prior to this role, Reid held various leadership positions at NeoGenomics Laboratories, including VP Alliances and Companion Diagnostics and Executive Director of Companion Diagnostics and Strategic Alliances. T. Scott also has experience in business development at Covance and LabCorp Clinical Trials. Earlier in their career, Reid co-founded Brightleaf Consulting Group and held roles in regulatory management and scientific research at Adherex Technologies, Nitrox LLC, and Cato Research. Reid holds an MBA from Fuqua School of Business.

T. Scott Reid's education history includes a Master of Business Administration (MBA) degree from Duke University - The Fuqua School of Business, specializing in Health Sector Management and Finance. T. Scott obtained this degree during the period of 2008 to 2009. Furthermore, they pursued a Doctor of Philosophy (PhD) degree in Biochemistry from Duke University, although the specific time frame is unclear. In addition, they completed their Bachelor of Science Honours (BScH) degree in Biochemistry from Queen's University. The exact years of their tenure at Duke University and Queen's University are unknown.